A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps
Latest Information Update: 15 Nov 2023
At a glance
- Drugs Omalizumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Acronyms POLYP 2
- Sponsors Roche
- 09 Nov 2023 Results of pooled post hoc analysis POLYP 1 and POLYP 2 and the open-label extension (OLE) trials assessing impact of the allergic and asthma status on omalizumab treatment in patients with CRSwNP published in the Annals of Allergy, Asthma and Immunology
- 18 May 2022 Results of (SYNAPSE [mepolizumab], SINUS 24/52 [dupilumab], POLYP 1/2 [omalizumab]) assessing the feasibility of conducting an ITC to obtain unbiased estimates of the relative efficacy of biologics for treatment of uncontrolled chronic rhinosinusitis with nasal polyps, presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 08 Nov 2021 Results of a s post hoc analysis assessed subgroups from the OLE study of the POLYP 1 (NCT03280550) and 2 (NCT03280537) to compare the efficacy of omalizumab in patients with nasal polyps with or without physician-reported allergic comorbidities presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology